(Q53799016)

19 May 2018

http://europepmc.org/abstract/MED/26839517

title

Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice. (English)

1 reference

19 May 2018

http://europepmc.org/abstract/MED/26839517

author name string

Christopher M Pieczonka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

Dimitrios Telonis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

Vladimir Mouraviev

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

David Albala

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

publication date

1 January 2015

1 reference

19 May 2018

http://europepmc.org/abstract/MED/26839517

published in

Reviews in urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

page(s)

203-210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

14 May 2020

cites work

1 reference

12 December 2020

Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer

1 reference

12 December 2020

The tumor microenvironment and its role in promoting tumor growth

1 reference

12 December 2020

Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Tumor evasion from T cell surveillance

1 reference

12 December 2020

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

1 reference

12 December 2020

Prostate cancer as a model for tumour immunotherapy

1 reference

12 December 2020

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

12 December 2020

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

1 reference

12 December 2020

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

12 December 2020

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer

1 reference

12 December 2020

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

1 reference

12 December 2020

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

1 reference

12 December 2020

Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research

1 reference

12 December 2020

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

12 December 2020

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer

1 reference

12 December 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

12 December 2020

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC4735666&resulttype=core&format=json

14 May 2020

1 reference